Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Liabilities and Shareholders Equity (2019 - 2025)

Harmony Biosciences Holdings' Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $1.3 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 27.26% year-over-year to $1.3 billion; the TTM value through Dec 2025 reached $4.6 billion, up 27.82%, while the annual FY2025 figure was $1.3 billion, 27.26% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $1.3 billion at Harmony Biosciences Holdings, up from $1.2 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.3 billion in Q4 2025 and bottomed at $337.3 million in Q1 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $769.0 million (2023), against an average of $757.4 million.
  • The largest annual shift saw Liabilities and Shareholders Equity rose 1.49% in 2021 before it soared 64.53% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $433.4 million in 2021, then surged by 55.47% to $673.9 million in 2022, then rose by 20.42% to $811.4 million in 2023, then increased by 23.14% to $999.2 million in 2024, then rose by 27.26% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Liabilities and Shareholders Equity are $1.3 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.1 billion (Q2 2025).